KR102314293B1 - Grpr-양성 암의 검출, 진단과 치료를 위한 grpr-길항제 - Google Patents

Grpr-양성 암의 검출, 진단과 치료를 위한 grpr-길항제 Download PDF

Info

Publication number
KR102314293B1
KR102314293B1 KR1020207034970A KR20207034970A KR102314293B1 KR 102314293 B1 KR102314293 B1 KR 102314293B1 KR 1020207034970 A KR1020207034970 A KR 1020207034970A KR 20207034970 A KR20207034970 A KR 20207034970A KR 102314293 B1 KR102314293 B1 KR 102314293B1
Authority
KR
South Korea
Prior art keywords
grpr
delete delete
cancer
antagonist
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207034970A
Other languages
English (en)
Korean (ko)
Other versions
KR20200139846A (ko
Inventor
테오도시아 마이나-노크
베르톨드 아써 노크
마리온 데 종 헨드릭스
Original Assignee
어드밴스드 액셀러레이터 애플리케이션즈 유에스에이, 인코퍼레이티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 어드밴스드 액셀러레이터 애플리케이션즈 유에스에이, 인코퍼레이티드. filed Critical 어드밴스드 액셀러레이터 애플리케이션즈 유에스에이, 인코퍼레이티드.
Publication of KR20200139846A publication Critical patent/KR20200139846A/ko
Application granted granted Critical
Publication of KR102314293B1 publication Critical patent/KR102314293B1/ko
Assigned to 어드밴스드 액셀러레이터 어플리케이션즈 인터내셔널 에스.에이. reassignment 어드밴스드 액셀러레이터 어플리케이션즈 인터내셔널 에스.에이. 권리의 전부이전등록 Assignors: 어드밴스드 액셀러레이터 애플리케이션즈 유에스에이, 인코퍼레이티드.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020207034970A 2012-09-25 2013-09-25 Grpr-양성 암의 검출, 진단과 치료를 위한 grpr-길항제 Active KR102314293B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261705513P 2012-09-25 2012-09-25
US61/705,513 2012-09-25
KR1020157007572A KR102190005B1 (ko) 2012-09-25 2013-09-25 Grpr-양성 암의 검출, 진단과 치료를 위한 grpr-길항제
PCT/US2013/061712 WO2014052471A1 (en) 2012-09-25 2013-09-25 Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157007572A Division KR102190005B1 (ko) 2012-09-25 2013-09-25 Grpr-양성 암의 검출, 진단과 치료를 위한 grpr-길항제

Publications (2)

Publication Number Publication Date
KR20200139846A KR20200139846A (ko) 2020-12-14
KR102314293B1 true KR102314293B1 (ko) 2021-10-19

Family

ID=49887190

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207034970A Active KR102314293B1 (ko) 2012-09-25 2013-09-25 Grpr-양성 암의 검출, 진단과 치료를 위한 grpr-길항제
KR1020157007572A Active KR102190005B1 (ko) 2012-09-25 2013-09-25 Grpr-양성 암의 검출, 진단과 치료를 위한 grpr-길항제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020157007572A Active KR102190005B1 (ko) 2012-09-25 2013-09-25 Grpr-양성 암의 검출, 진단과 치료를 위한 grpr-길항제

Country Status (19)

Country Link
US (7) US9839703B2 (https=)
EP (2) EP2900279B1 (https=)
JP (4) JP6562838B2 (https=)
KR (2) KR102314293B1 (https=)
AU (4) AU2013323596C1 (https=)
BR (1) BR112015006453B1 (https=)
CA (2) CA3114832A1 (https=)
DK (1) DK2900279T3 (https=)
ES (1) ES2745635T3 (https=)
HR (1) HRP20191620T1 (https=)
HU (1) HUE045724T2 (https=)
IL (4) IL312551B2 (https=)
LT (1) LT2900279T (https=)
MX (1) MX362675B (https=)
PL (1) PL2900279T3 (https=)
PT (1) PT2900279T (https=)
RU (1) RU2693465C9 (https=)
SI (1) SI2900279T1 (https=)
WO (1) WO2014052471A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2841238C (en) * 2011-07-08 2019-10-01 Biosynthema Inc. Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors
PL2900279T3 (pl) * 2012-09-25 2020-05-18 Advanced Accelerator Applications Usa, Inc. Antagonisty grpr do wykrywania, diagnostyki i leczenia raka grpr-pozytywnego
EP3015462A1 (en) * 2014-10-29 2016-05-04 OctreoPharm Schiences GmbH Enantiopure chelating agents for chelator coupled pharmaceuticals, corresponding preparation method thereof and chelator coupled pharmaceuticals
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
US11857352B2 (en) 2016-09-06 2024-01-02 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
RU2755181C2 (ru) 2016-11-28 2021-09-14 Байер Фарма Акциенгезельшафт Новые хелатные соединения гадолиния с высокой релаксивностью для применения в магнитно-резонансной визуализации
DK3568205T3 (da) 2017-01-12 2023-10-09 Radiomedix Inc Behandling af cancerceller, der overeksprimerer somatostatinreceptorer ved at anvende radioisotop-chelaterede ocreotid-derivater
CN113195005B (zh) * 2018-10-12 2023-07-21 国际先进加速器应用公司 包含放射性标记的grpr拮抗剂和表面活性剂的药物组合物
WO2021068051A1 (en) * 2018-11-13 2021-04-15 Provincial Health Services Authority Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
CN113164628A (zh) 2018-11-23 2021-07-23 拜耳股份有限公司 造影介质制剂及其制备方法
CN114728088A (zh) * 2019-09-16 2022-07-08 诺华股份有限公司 稳定的浓缩的放射性药物组合物
TWI878344B (zh) * 2019-09-17 2025-04-01 瑞士商諾華公司 放射性標記grpr拮抗劑之方法及其套組
JP2022549258A (ja) * 2019-09-24 2022-11-24 ノバルティス アーゲー セラノスティックスとして使用するための放射性標識ｇｒｐｒアンタゴニスト
EP4076541A1 (en) * 2019-12-19 2022-10-26 Technische Universität München Modified grpr antagonist peptides for imaging and therapy of cancer
CA3246188A1 (en) 2022-03-25 2023-09-28 The University Of British Columbia Radiolabeled compounds for in vivo imaging of the gastrin-releasing peptide (GRPR) receptor and treatment of GRPR-related disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019647A (en) 1988-05-24 1991-05-28 Merck & Co., Inc. Gastrin releasing peptide antagonist
JP2006528644A (ja) 2003-07-24 2006-12-21 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 安定な放射性医薬品組成物およびその製法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943561A (en) 1988-11-28 1990-07-24 Merck & Co., Inc. Gastrin releasing peptide antagonist
US5028692A (en) * 1989-04-25 1991-07-02 Merck & Co., Inc. Gastrin releasing peptide antagonist
IL96216A0 (en) 1989-11-06 1991-08-16 Erba Carlo Spa Peptide derivatives,their preparation and pharmaceutical compositions containing them
EP0626973A1 (en) 1992-02-07 1994-12-07 Merrell Pharmaceuticals Inc. Phenylalanine analogs of bombesin
US5620955A (en) * 1993-06-18 1997-04-15 Peptide Technologies Corporation Bombesin receptor antagonists and uses thereof
US6545125B1 (en) 1997-11-18 2003-04-08 Chugai Seiyaku Kabushiki Kaisha Compounds with antitumor activity
EP2100900A1 (en) * 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
MX2013005697A (es) 2010-11-22 2014-08-01 Piramal Imaging Sa Analogos de bombesina marcados con lutecio 177, para radioterapia.
CA2841238C (en) * 2011-07-08 2019-10-01 Biosynthema Inc. Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors
PL2900279T3 (pl) * 2012-09-25 2020-05-18 Advanced Accelerator Applications Usa, Inc. Antagonisty grpr do wykrywania, diagnostyki i leczenia raka grpr-pozytywnego

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019647A (en) 1988-05-24 1991-05-28 Merck & Co., Inc. Gastrin releasing peptide antagonist
JP2006528644A (ja) 2003-07-24 2006-12-21 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 安定な放射性医薬品組成物およびその製法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
David C. Heimbrook 외. Gastrin Releasing Peptide Antagonists with Improved Potency and Stability. J. Med. Chem. 1991, Vol. 34, pp. 2102-2107*
Wael R. Abd-Elgaliel 외. Design, Synthesis, and Biological Evaluation of an Antagonist-Bombesin Analogue as Targeting Vector. Bioconjugate Chem. 2008, Vol. 19, pp. 2040-2048*

Also Published As

Publication number Publication date
IL256649B (en) 2020-08-31
IL276300B2 (en) 2024-10-01
IL276300A (en) 2020-09-30
AU2018204513B2 (en) 2019-05-23
AU2019216714B2 (en) 2021-04-08
BR112015006453A2 (https=) 2017-09-05
CA2886068A1 (en) 2014-04-03
JP7358430B2 (ja) 2023-10-10
AU2013323596C1 (en) 2020-10-15
AU2021201914B2 (en) 2024-09-05
RU2015115529A (ru) 2016-11-20
IL312551A (en) 2024-07-01
US20150265732A1 (en) 2015-09-24
RU2693465C2 (ru) 2019-07-03
RU2693465C9 (ru) 2020-08-14
JP6562838B2 (ja) 2019-08-21
JP2021191800A (ja) 2021-12-16
IL312551B2 (en) 2025-12-01
JP2019167365A (ja) 2019-10-03
JP7534498B2 (ja) 2024-08-14
AU2019216714A1 (en) 2019-09-05
PL2900279T3 (pl) 2020-05-18
US20220008568A1 (en) 2022-01-13
US12064490B2 (en) 2024-08-20
US20240366812A1 (en) 2024-11-07
LT2900279T (lt) 2019-11-11
MX2015003772A (es) 2015-11-09
US20210346528A1 (en) 2021-11-11
JP6997135B2 (ja) 2022-02-04
RU2019119378A (ru) 2020-10-23
AU2021201914A1 (en) 2021-04-29
AU2013323596A1 (en) 2015-04-02
US12064489B2 (en) 2024-08-20
EP2900279A1 (en) 2015-08-05
PT2900279T (pt) 2019-10-14
WO2014052471A1 (en) 2014-04-03
KR20150090886A (ko) 2015-08-06
US12064491B2 (en) 2024-08-20
IL237844B (en) 2018-01-31
HUE045724T2 (hu) 2020-01-28
MX362675B (es) 2019-01-30
EP2900279B1 (en) 2019-08-14
US20210346529A1 (en) 2021-11-11
SI2900279T1 (sl) 2019-12-31
AU2018204513C1 (en) 2020-10-15
BR112015006453B1 (pt) 2023-10-17
AU2018204513A1 (en) 2018-07-12
IL256649A (en) 2018-02-28
US20180133349A1 (en) 2018-05-17
KR102190005B1 (ko) 2020-12-15
KR20200139846A (ko) 2020-12-14
CA2886068C (en) 2021-06-22
US20200009276A1 (en) 2020-01-09
ES2745635T3 (es) 2020-03-03
US11083805B2 (en) 2021-08-10
JP2015533119A (ja) 2015-11-19
IL312551B1 (en) 2025-08-01
US9839703B2 (en) 2017-12-12
CA3114832A1 (en) 2014-04-03
HRP20191620T1 (hr) 2019-12-13
JP2023126440A (ja) 2023-09-07
EP3536347A1 (en) 2019-09-11
AU2013323596B2 (en) 2018-03-22
DK2900279T3 (da) 2019-09-30
IL276300B1 (en) 2024-06-01

Similar Documents

Publication Publication Date Title
JP7534498B2 (ja) Ｇｒｐｒ陽性ガンの検出、診断及び治療のためのｇｒｐｒアンタゴニスト
Smith et al. Radiochemical investigations of gastrin-releasing peptide receptor-specific [99mTc (X)(CO) 3-Dpr-Ser-Ser-Ser-Gln-Trp-Ala-Val-Gly-His-Leu-Met-(NH2)] in PC-3, tumor-bearing, rodent models: syntheses, radiolabeling, and in vitro/in vivo studies where Dpr= 2, 3-diaminopropionic acid and X= H2O or P (CH2OH) 3
EP1368064B1 (en) Synthesis of tetradentate peptide-chelate conjugates for colorectal cancer diagnosis
Zhang et al. [99mTc (CO) 3]+ and [99mTcO2]+ Radiolabeled cyclic melanotropin peptides for melanoma SPECT imaging
RU2821944C2 (ru) Антагонисты grpr для обнаружения, диагностики и лечения grpr-позитивного онкологического заболевания
WO2026058257A1 (en) Grpr binding peptides

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R17 Change to representative recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R17-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R14-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)